company background image
ARX logo

Aroa Biosurgery ASX:ARX Stock Report

Last Price

AU$0.63

Market Cap

AU$215.1m

7D

0.8%

1Y

-30.6%

Updated

15 Jun, 2024

Data

Company Financials +

ARX Stock Overview

Engages in the development, manufacture, and sale of medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

ARX fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Aroa Biosurgery Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aroa Biosurgery
Historical stock prices
Current Share PriceAU$0.63
52 Week HighAU$0.99
52 Week LowAU$0.47
Beta0.73
1 Month Change25.00%
3 Month Change17.92%
1 Year Change-30.56%
3 Year Change-39.32%
5 Year Changen/a
Change since IPO-53.70%

Recent News & Updates

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Recent updates

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Shareholder Returns

ARXAU BiotechsAU Market
7D0.8%-0.2%-1.7%
1Y-30.6%4.9%7.0%

Return vs Industry: ARX underperformed the Australian Biotechs industry which returned 4.9% over the past year.

Return vs Market: ARX underperformed the Australian Market which returned 7% over the past year.

Price Volatility

Is ARX's price volatile compared to industry and market?
ARX volatility
ARX Average Weekly Movement7.2%
Biotechs Industry Average Movement10.7%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market3.2%

Stable Share Price: ARX has not had significant price volatility in the past 3 months.

Volatility Over Time: ARX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aBrian Wardaroabio.com

Aroa Biosurgery Limited engages in the development, manufacture, and sale of medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds.

Aroa Biosurgery Limited Fundamentals Summary

How do Aroa Biosurgery's earnings and revenue compare to its market cap?
ARX fundamental statistics
Market capAU$215.13m
Earnings (TTM)-AU$9.87m
Revenue (TTM)AU$64.11m

3.4x

P/S Ratio

-21.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARX income statement (TTM)
RevenueNZ$69.07m
Cost of RevenueNZ$10.09m
Gross ProfitNZ$58.97m
Other ExpensesNZ$69.60m
Earnings-NZ$10.63m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.031
Gross Margin85.39%
Net Profit Margin-15.39%
Debt/Equity Ratio0%

How did ARX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.